Q1 Earnings Estimate for BNTC Issued By Leerink Partnrs

Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Benitec Biopharma in a research report issued on Monday, October 14th. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will post earnings per share of ($0.54) for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Benitec Biopharma's current full-year earnings is ($2.46) per share. Leerink Partnrs also issued estimates for Benitec Biopharma's Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at ($1.39) EPS.

BNTC has been the subject of several other research reports. JMP Securities raised their price target on Benitec Biopharma from $16.00 to $18.00 and gave the stock a "market outperform" rating in a research report on Monday. Guggenheim started coverage on Benitec Biopharma in a research report on Thursday, September 12th. They set a "buy" rating and a $17.00 price target for the company. Leerink Partners started coverage on Benitec Biopharma in a research report on Monday, July 22nd. They set an "outperform" rating and a $13.00 price target for the company. Finally, Oppenheimer started coverage on Benitec Biopharma in a research report on Wednesday. They set an "outperform" rating and a $35.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $22.60.

Benitec Biopharma Price Performance

Benitec Biopharma stock traded up $1.41 during mid-day trading on Thursday, hitting $11.22. 51,996 shares of the company were exchanged, compared to its average volume of 46,744. The business's 50 day simple moving average is $9.13 and its two-hundred day simple moving average is $8.33. The company has a market capitalization of $105.11 million, a P/E ratio of -5.87 and a beta of 0.90. Benitec Biopharma has a 12-month low of $2.69 and a 12-month high of $12.89.

Institutional Investors Weigh In On Benitec Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC purchased a new stake in shares of Benitec Biopharma in the second quarter valued at $5,881,000. Janus Henderson Group PLC grew its position in shares of Benitec Biopharma by 35.5% in the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company's stock valued at $1,266,000 after purchasing an additional 64,092 shares during the period. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma in the second quarter valued at $358,000. Finally, GAMMA Investing LLC boosted its holdings in Benitec Biopharma by 20.3% in the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 1,102 shares during the last quarter. Hedge funds and other institutional investors own 52.19% of the company's stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.